Alnylam Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Alnylam Pharmaceuticals has been growing earnings at an average annual rate of 43.4%, while the Biotechs industry saw earnings growing at 37.7% annually. Revenues have been growing at an average rate of 35.7% per year. Alnylam Pharmaceuticals's return on equity is 50%, and it has net margins of 12.5%.
Key information
43.43%
Earnings growth rate
44.32%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 35.66% |
| Return on equity | 50.03% |
| Net Margin | 12.55% |
| Next Earnings Update | 30 Jul 2026 |
Recent past performance updates
Recent updates
Seeking Alpha • Jul 16
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
Summary I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with strong clinical data and $890 million in Q1 2026 revenue. ALNY's robust cash position ($3.0 billion) and GAAP profitability materially reduce investment risk and support pipeline development. Key risks include AMVUTTRA's market penetration, payer dynamics, and phase 3 outcomes for nucresiran, but current valuation discounts near-term strengths. Read the full article on Seeking Alpha
Narrative Update • Jul 14
ALNY: ATTR-CM Competitive Shift And AI Expansion Will Drive Future Upside
Analysts have modestly increased their fair value estimate for Alnylam Pharmaceuticals, with the price target moving from about $310.31 to $320.21, as they update models to reflect shifting expectations for long term revenue growth, profit margins, and future P/E assumptions following recent mixed research commentary on the ATTR-CM franchise. Analyst Commentary Recent research on Alnylam Pharmaceuticals reflects a split view, with some firms lifting price targets and others trimming them as they reassess assumptions for the ATTR-CM opportunity, competitive pressures, and execution risks around upcoming data and launches.
Narrative Update • Jun 30
ALNY: Cardiomyopathy Expansion And AI Partnerships Will Drive Long Term Upside
Alnylam Pharmaceuticals' analyst-derived fair value estimate has been revised from $491.92 to $434.72 as analysts temper revenue growth and margin assumptions, following mixed adjustments to price targets and updated views on the Amvuttra launch and TTR franchise trajectory. Analyst Commentary Recent commentary on Alnylam Pharmaceuticals shows a mix of optimism around the long term potential of the TTR franchise and more cautious views on execution and valuation in the near term.
Narrative Update • Jun 16
ALNY: TTR Franchise Execution And 2030 Plan Will Support Stock Repricing
The analyst price target for Alnylam Pharmaceuticals has been adjusted to $550. This move reflects updated views on fair value, growth assumptions, and profitability, while aligning with recent Street commentary that highlights both the pullback in the stock and ongoing expectations around Amvuttra's launch and competitive pressures.Narrative Update • Jun 02
ALNY: Fair View Balances ATTR-CM Data Progress With Competition And Pipeline Execution
Alnylam Pharmaceuticals' analyst fair value estimate has edged down by about $1 to $310.31, as analysts balance slightly softer modeled revenue growth and a marginally higher discount rate with a stronger profit margin outlook and ongoing support from recent price target moves and coverage initiations. Analyst Commentary Street research on Alnylam Pharmaceuticals currently reflects a mix of optimism on the drug pipeline and caution on how much of that potential is already reflected in the share price.Narrative Update • May 11
ALNY: Fair View Weighs TTR Execution Risks Against Cardiovascular Pipeline Progress
Analysts have nudged Alnylam Pharmaceuticals' fair value estimate to $311.72 from $310.00, reflecting updated assumptions for slightly lower revenue growth and profit margins, as well as a higher future P/E multiple based on recent shifts in price targets and commentary across the Street. Analyst Commentary Recent research has highlighted a mixed backdrop for Alnylam Pharmaceuticals, with some firms revising targets higher on product execution while others voice concern that the stock already reflects optimistic outcomes.Narrative Update • Apr 20
ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.Narrative Update • Apr 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' analyst price targets have been reset across the Street, with several cuts from firms now clustering in a roughly $249 to $570 range, as analysts balance concerns that shares are "priced to perfection" and that long term expectations may be too rich, against continued confidence in the RNAi platform and the strong Amvuttra launch in TTR and ATTR-CM. Analyst Commentary Recent research updates show a split tape on Alnylam, with some firms trimming targets and others leaning into the story as Amvuttra execution and RNAi platform confidence remain central themes.Narrative Update • Mar 23
ALNY: TTR Franchise Momentum Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' updated analyst price targets show a wide reset across the Street, with cuts from firms now clustered around the $249 to $570 range. Analysts are balancing strong Amvuttra momentum and the RNAi platform's potential with concerns that the shares had been priced for very optimistic growth and competition assumptions.Narrative Update • Mar 07
ALNY: TTR Execution Will Support Confidence In 2026 Revenue Outlook
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals by $14 to $566, reflecting higher discount rates and more conservative assumptions for revenue growth and profit margins, even as they continue to highlight strong Amvuttra traction and supportive 2026 guidance in recent research. Analyst Commentary Recent research paints a mixed picture on valuation, but there is still a clear cluster of optimistic views around Alnylam's execution, especially in its TTR franchise and Amvuttra rollout.Narrative Update • Feb 21
ALNY: Fair View Weighs TTR Franchise Guidance Against Launch Execution Risks
The updated analyst price target for Alnylam Pharmaceuticals has decreased by about $45 per share, as analysts refresh their models with slightly softer revenue growth assumptions, a modestly higher long-term profit margin, and a reduced future P/E multiple. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed backdrop, with several firms revisiting their models following Q4 results, preannounced revenue figures, and updated 2026 guidance.Narrative Update • Feb 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Guidance
Analysts have trimmed their average price targets on Alnylam Pharmaceuticals by roughly $35 to $70, largely reflecting updated views on Amvuttra revenue trajectories, competitive pressures in ATTR-CM and recent guidance that, while still supported by continued TTR franchise momentum, has prompted more measured growth assumptions. Analyst Commentary Recent research updates show a mixed but generally constructive tone on Alnylam, with several bullish analysts pointing to execution on the TTR franchise, early Amvuttra traction in ATTR-CM and management guidance as key supports for valuation.Narrative Update • Jan 23
ALNY: TTR Franchise Momentum Will Drive 2026 Revenue Guidance Confidence
Narrative Update: Alnylam Pharmaceuticals Price Target Revision The analyst price target for Alnylam Pharmaceuticals has been raised by $10 to $580, as analysts weigh mixed target changes across the Street alongside company guidance that highlights ongoing momentum in the TTR franchise and a positive outlook for revenue driven by Amvuttra. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has been active, with several price target revisions and fresh commentary following the company’s Q3 results, preliminary Q4 figures, and updated 2025 and 2026 revenue guidance.Narrative Update • Jan 09
ALNY: Fair View Balances TTR Guidance Upside And Launch Deceleration Risk
Alnylam Pharmaceuticals' analyst fair value estimate has been raised from about $259.89 to about $368.22, as analysts factor in stronger modeled revenue growth, higher projected profitability, and a reset to more moderate future P/E expectations following recent research updates around Amvuttra uptake and revised TTR guidance. Analyst Commentary Recent research on Alnylam highlights a mixed backdrop.Narrative Update • Dec 26
ALNY: Cardiomyopathy Launch Will Drive Future Upside Despite Growing Competitive Pressures
Analysts have modestly lifted their price target for Alnylam Pharmaceuticals, reflecting stronger Amvuttra driven TTR revenue expectations and a series of Street target increases into the mid 400s to mid 500s, even as they highlight a more balanced risk and the potential for range bound trading into 2026. Analyst Commentary Recent Street research reflects a constructive but increasingly balanced view on Alnylam, with multiple firms lifting price targets into the mid 400s to mid 500s on the back of stronger Amvuttra traction and higher TTR revenue expectations, while also flagging valuation and competitive considerations that could cap upside.Narrative Update • Dec 12
ALNY: Cardiomyopathy Launch Will Drive Future Momentum Despite Intensifying Competition
Alnylam Pharmaceuticals’ fair value estimate has nudged higher to approximately $493 from about $489 as analysts lift price targets into the mid to high $400s, citing stronger than expected Amvuttra driven TTR revenue growth and a still rich but increasingly supported long term earnings profile. Analyst Commentary Street research remains broadly constructive on Alnylam, with multiple firms lifting price targets into the mid to high $400s and several pushing above $500.Narrative Update • Nov 27
ALNY: Future Momentum In Cardiomyopathy Will Meet Rising Competition And Pricing Pressures
The analyst price target for Alnylam Pharmaceuticals has increased by approximately $9 to $489, as analysts cite strong Amvuttra sales, raised revenue guidance, and resilient commercial momentum as key factors supporting a more optimistic outlook. Analyst Commentary Analysts have provided a range of perspectives following Alnylam Pharmaceuticals’ recent performance, with several raising their price targets and highlighting both catalysts and areas of caution for the company’s outlook.Narrative Update • Nov 12
ALNY: Momentum In Cardiomyopathy Segment Will Face Intensifying Competitive Risks Ahead
Alnylam Pharmaceuticals’ fair value estimate has increased from $467.94 to $480.17. This change reflects analysts' optimism about robust Amvuttra sales, raised revenue guidance, and an improved profit margin outlook.Narrative Update • Oct 29
Cardiomyopathy Launches And Pipeline Expansion Will Sustain Momentum Into 2025
Analysts have increased their price target for Alnylam Pharmaceuticals by approximately $16, citing stronger than expected product launches and continued commercial momentum. Analyst Commentary Following a series of upward price target revisions, Wall Street analysts remain broadly upbeat about Alnylam Pharmaceuticals’ near-term commercial performance and long-term prospects.Narrative Update • Oct 14
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals' analyst price targets have recently moved higher, with analysts citing stronger commercial performance of Amvuttra and encouraging data from pipeline assets as drivers behind the upward revisions. The cited targets have climbed by as much as $55 to $583 per share.Narrative Update • Sep 23
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.Narrative Update • Sep 08
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam’s modestly lower consensus price target to $421.20 reflects both strong near-term Amvuttra uptake in ATTR-CM and positive revenue outlook, tempered by mixed KARDIA-3 data for zilebesiran and resulting slight valuation adjustment. Analyst Commentary Bullish analysts cited strong commercial performance and encouraging uptake for Amvuttra, particularly following its approval and launch in ATTR-CM (transthyretin amyloid cardiomyopathy), as a key driver for raising price targets.Analysis Article • Aug 01
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Mar 21
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Summary Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside. Alnylam's proven R&D engine and above-average success ratio make it a compelling long-term biotech investment despite arguably modest immediate upside. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Alnylam: Waiting For Regulatory Updates In March
Summary Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows. Alnylam expects non-GAAP operating profitability in 2025. Successful regulatory approvals and strong commercial execution could push Alnylam's share price to new all-time highs within 6–12 months. Read the full article on Seeking AlphaRevenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Alnylam Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 4,287 | 538 | 1,293 | 1,420 |
| 31 Dec 25 | 3,714 | 314 | 1,211 | 1,320 |
| 30 Sep 25 | 3,210 | 83 | 1,181 | 1,248 |
| 30 Jun 25 | 2,462 | -280 | 1,080 | 1,160 |
| 31 Mar 25 | 2,348 | -230 | 1,005 | 1,130 |
| 31 Dec 24 | 2,248 | -278 | 976 | 1,126 |
| 30 Sep 24 | 2,095 | -332 | 878 | 1,098 |
| 30 Jun 24 | 2,344 | -73 | 856 | 1,080 |
| 31 Mar 24 | 2,003 | -332 | 823 | 1,035 |
| 31 Dec 23 | 1,828 | -440 | 796 | 1,004 |
| 30 Sep 23 | 1,724 | -510 | 808 | 994 |
| 30 Jun 23 | 1,237 | -1,064 | 845 | 987 |
| 31 Mar 23 | 1,143 | -1,065 | 800 | 944 |
| 31 Dec 22 | 1,037 | -1,131 | 771 | 883 |
| 30 Sep 22 | 961 | -1,182 | 747 | 850 |
| 30 Jun 22 | 884 | -981 | 653 | 799 |
| 31 Mar 22 | 880 | -893 | 628 | 776 |
| 31 Dec 21 | 844 | -853 | 621 | 792 |
| 30 Sep 21 | 749 | -838 | 619 | 713 |
| 30 Jun 21 | 688 | -887 | 662 | 662 |
| 31 Mar 21 | 571 | -876 | 663 | 617 |
| 31 Dec 20 | 493 | -858 | 588 | 655 |
| 30 Sep 20 | 401 | -891 | 646 | 620 |
| 30 Jun 20 | 345 | -846 | 594 | 624 |
| 31 Mar 20 | 286 | -886 | 574 | 637 |
| 31 Dec 19 | 220 | -886 | 534 | 600 |
| 30 Sep 19 | 169 | -821 | 482 | 534 |
| 30 Jun 19 | 101 | -858 | 477 | 515 |
| 31 Mar 19 | 86 | -802 | 446 | 491 |
| 31 Dec 18 | 75 | -761 | 425 | 463 |
| 30 Sep 18 | 92 | -692 | 379 | 454 |
| 30 Jun 18 | 107 | -570 | 306 | 414 |
| 31 Mar 18 | 93 | -525 | 264 | 370 |
| 31 Dec 17 | 90 | -491 | 230 | 360 |
| 30 Sep 17 | 69 | -462 | 191 | 346 |
| 30 Jun 17 | 66 | -443 | 166 | 349 |
| 31 Mar 17 | 59 | -414 | 137 | 342 |
| 31 Dec 16 | 47 | -410 | 119 | 352 |
| 30 Sep 16 | 37 | -388 | 106 | 333 |
| 30 Jun 16 | 30 | -361 | 98 | 305 |
| 31 Mar 16 | 30 | -342 | 93 | 291 |
| 31 Dec 15 | 41 | -290 | 82 | 255 |
| 30 Sep 15 | 58 | -221 | 78 | 229 |
Quality Earnings: ALNY has high quality earnings.
Growing Profit Margin: ALNY became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALNY has become profitable over the past 5 years, growing earnings by 43.4% per year.
Accelerating Growth: ALNY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ALNY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (59.3%).
Return on Equity
High ROE: Whilst ALNY's Return on Equity (50.03%) is outstanding, this metric is skewed due to their high level of debt.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/24 18:19 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alnylam Pharmaceuticals, Inc. is covered by 56 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |
| Emily Bodnar | Berenberg |